On what date did the GSK (GSK) insider share sale occur?

The sale of 6,000 GSK ordinary shares took place on 2025-12-05.

GSK discloses insider sale of 6,000 shares at £18.287 each

Q: What insider transaction did GSK (GSK) disclose in this report?

GSK disclosed that Sally Jackson, SVP, Global Communications & CEO Office, carried out a sale of GSK ordinary shares, which is reported as a person discharging managerial responsibilities (PDMR) transaction.

Q: How many GSK (GSK) shares were sold and at what price?

The transaction involved the sale of 6,000 ordinary shares of GSK at a price of £18.2870 per share.

Q: Where were the GSK (GSK) shares traded in this transaction?

The shares were traded on the London Stock Exchange (XLON).

Q: Who is the person involved in this GSK (GSK) PDMR transaction?

The person involved is Sally Jackson, who holds the position of SVP, Global Communications & CEO Office at GSK.

Q: What type of shares were sold in this GSK (GSK) transaction?

The transaction related to GSK ordinary shares of 31 ¼ pence each, identified by ISIN GB00BN7SWP63.

Q: What does this GSK (GSK) filing mainly communicate to investors?

It primarily communicates a routine regulatory disclosure of a share dealing by a senior GSK manager, as required for persons discharging managerial responsibilities.

GSK plc reported a share transaction by a senior manager.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reported a share transaction by a senior manager. Sally Jackson, SVP, Global Communications & CEO Office, sold 6,000 ordinary shares of GSK on the London Stock Exchange. The shares were sold at a price of £18.2870 per share on 2025-12-05. This disclosure is a routine notification of dealings by a person discharging managerial responsibilities in GSK’s securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this report?

GSK disclosed that Sally Jackson, SVP, Global Communications & CEO Office, carried out a sale of GSK ordinary shares, which is reported as a person discharging managerial responsibilities (PDMR) transaction.

How many GSK (GSK) shares were sold and at what price?

The transaction involved the sale of 6,000 ordinary shares of GSK at a price of £18.2870 per share.

Where were the GSK (GSK) shares traded in this transaction?

The shares were traded on the London Stock Exchange (XLON).

Who is the person involved in this GSK (GSK) PDMR transaction?

The person involved is Sally Jackson, who holds the position of SVP, Global Communications & CEO Office at GSK.

What type of shares were sold in this GSK (GSK) transaction?

The transaction related to GSK ordinary shares of 31 ¼ pence each, identified by ISIN GB00BN7SWP63.

What does this GSK (GSK) filing mainly communicate to investors?

It primarily communicates a routine regulatory disclosure of a share dealing by a senior GSK manager, as required for persons discharging managerial responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/09/2025 - 12:33 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications & CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Sale of 6,000 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.2870	6,000

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-12-05
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: December 09, 2025

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR